Zynerba Press Releases

19 Jul 18
Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock

12 Jul 18
Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome

9 Jul 18
Zynerba Pharmaceuticals Initiates CONNECT-FX, a Pivotal Clinical Trial of ZYN002 in Fragile X Syndrome

5 Jul 18
Zynerba Pharmaceuticals Announces Top Line Results from ZYN001 THC-Prodrug Patch Phase 1 Study

31 May 18
Zynerba Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

8 May 18
Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights

25 Apr 18
Zynerba Pharmaceuticals Announces Twelve Month ZYN002 Data from STAR 2 Study in Patients with Focal Seizures at the 2018 Annual Meeting of the American Academy of Neurology (AAN)

23 Apr 18
Zynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data at the 16th NFXF International Fragile X Conference in July 2018

16 Apr 18
Zynerba Pharmaceuticals Appoints John P. Butler to Board of Directors

10 Apr 18
Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies (DEE)